Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that The City University of New York (CUNY), the largest urban university in the United States, has extended its health services contract for COVID-19 testing and vaccine policy management with the Company's wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), for 12 months through July 202

Applied DNA Awarded Extension of Health Services Contract with The City University of New York

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that it has received approximately $3.6 million in net proceeds following an exercise of Series B warrants by an institutional investor in the Company. The Series B warrants exercised were issued in connection with a public offering that closed on August 8, 2022. Each Series B warrant entitles its owner to purchase one share o

Applied DNA Receives Approximately $3.6 Million in Net Proceeds from Warrant Exercise

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that Dr. James A. Hayward, president and CEO, and Beth Jantzen, chief financial officer, will host a conference call and webcast on Thursday, August 11, 2022, at 4:30 p.m. ET to provide financial results and corporate updates for the fiscal third quarter of 2022. To access the conference call: U.S. calle

Applied DNA to Host Conference Call and Webcast Discussing Fiscal 2022 Third Quarter Results and Corporate Updates

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc., (NASDAQ: APDN) (the “Company” or “Applied DNA”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common sto

Applied DNA Announces Closing of Upsized $12 Million Public Offering

Geovax Labs

The White House has declared monkeypox a public health emergency. Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the alarm.

3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency

Shares of Applied DNA Sciences Inc. APDN, +9.93% jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test.

Applied DNA stock surges again, for 4-day gain of more than 870%

Aethlon Medical

Chembio Diagnostics

E-Home Household Service Holdings Ltd

NanoViricides

SIGA Technologies

Tonix Pharmaceuticals Hld

10 monkeypox stocks and monkeypox penny stocks to watch The post 10 Top Monkeypox Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Monkeypox Stocks To Watch Right Now

Shares of Applied DNA Sciences Inc. APDN, -4.15% pulled back 5.1% in morning trading Thursday, after the biotechnology company announced the pricing of its "upsized" public equity offering. The stock's decline comes after it blasted 502.9% higher over the past two days, in the wake of its announcement that it had initiated a validation of its monkeypox virus test.

Applied DNA Sciences pulls back after 6-fold surge in 2 days, after 'upsized' equity offering prices

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc., (NASDAQ: APDN) (the “Company” or “Applied DNA”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the pricing of a public offering of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined offeri

Applied DNA Announces Pricing of $12 Million Upsized Public Offering, Priced at a Premium to Market Under Nasdaq Rules

The stock price of Applied DNA Sciences (APDN) increased by 46.43% in the previous trading session. These are some details you should know.

Applied DNA Sciences (APDN) Stock Surged 46.43%: Details You Should Know

Molecular technology firm Applied DNA Sciences (NASDAQ: APDN ) — which among its many specialties include polymerase chain reaction (PCR)-based solutions — recently initiated an analytical validation of its PCR test for the monkeypox virus. The test is designed to identify the monkeypox virus' genetic signature.

Applied DNA Sciences (APDN) Stock Soars Another 80%

Shares of Applied DNA Sciences Inc. APDN, +311.16% shot up 84.0% in premarket trading, after they more than quadrupled in the previous session (up 311.2%) in the wake of the biotechnology company's announcement that it had initiated a validation of a monkeypox virus test. The two day rally comes after the stock tied its record-low close of 68 cents on Aug. 1, after first setting that record low on July 25.

Applied DNA stock soars more than 80% active trading, after quadrupling in the previous session

Here's what you need to know about buying penny stocks today The post Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Premarket on August 3rd? 3 to Watch

A step closer to public testing for monkeypox, the update sent trading volume soaring to over 82 million shares, compared to a daily average of 153,000.

A small biotech firm's stock spiked 425% after giving a positive update on a PCR test for monkeypox

Shares of Applied DNA Sciences Inc. APDN, +390.46% skyrocketed 353.7% higher in very volatile trading Tuesday, after the biotechnology company said it initiated validation of a monkeypox virus test. Trading volume spiked to 73.1 million shares, compared with the full-day average of about 256,450 shares.

Applied DNA Sciences blasts more than 350% higher after initiating validation of monkeypox virus test

Source: Zeedign.com / Shutterstock.com Applied DNA (NASDAQ: APDN ) stock is rocketing higher on Tuesday after the company revealed its starting analytical validation of a monkeypox virus test. The new test from Applied DNA has been developed as a NYSDOH Laboratory Developed Test.

Why Is Applied DNA (APDN) Stock Up 212% Today?

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LDT--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. The test has been developed as a type of NYSDOH Laboratory Developed Test (

Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test Specific to Monkeypox Virus

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LNP--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular immunity against SARS-CoV-2. The manuscript, authored by LineaRx, the Company's majority-owned biotherapeutics subsidiary, and LineaRx's development partner, EvviVax, S.R.L., further establishe

Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA (linDNA) as an IVT template for mRNA production at the 2nd Annual mRNA-Based Therapeutics Summit on July 26-28, 2022, in Boston, Massachusett

Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA expands industry awareness of LinearDNA platform as an alternative to plasmid DNA for therapeutic applications.

Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #DNAtraceability--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, has been increasing its engagement with all stakeholders in anticipation of the June 21, 2022, effective date of the “rebuttable presumption” standard under the Uyghur Forced Labor Prevention Act (UFLPA) signed into law on December 23, 2021. Under the UFLPA, all imports that originate from China's Xinjiang Uyghur Autonomous Region (XUAR) or otherwise us

U.S. Government Guidance Permits DNA Traceability and Isotopic Testing as Evidence under Uyghur Forced Labor Prevention Act

STONY BROOK, N.Y. and ROME, Italy--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA's LinearDNA™ platform to produce veterinary DNA cancer vaccines. LinearDNA is Applied DNA's proprieta

Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President & Chief Executive Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Jason McCarty - Maxim Group Jon Salmanson - Cantella Operator Good evening, and welcome to Applied DNA Sciences' Fiscal Second Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Revenues at Record $6.2 Million, up 130% Year-over-Year; Cash at $6.5 Million Inclusive of Net Proceeds from Offering and Strong Cash Collections.

Applied DNA Reports Second Quarter Fiscal 2022 Financial Results

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #LinearDNA--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events' sub-page of the

News for Applied DNA Sciences Stock (APDN)